Difference between revisions of "ICRP Glossary"
Jump to navigation
Jump to search
| Line 39: | Line 39: | ||
*[[Accountability]] | *[[Accountability]] | ||
| + | |||
| + | *[[Accreditation]] | ||
*[[Action Level]] | *[[Action Level]] | ||
*[[Activation]] | *[[Activation]] | ||
| + | |||
| + | *[[Active detection system]] | ||
*[[Active (red) bone marrow]] | *[[Active (red) bone marrow]] | ||
| Line 55: | Line 59: | ||
*[[Acute radiation syndrome]] | *[[Acute radiation syndrome]] | ||
| + | |||
| + | *[[Additional dose]] | ||
*[[Adaptive response]] | *[[Adaptive response]] | ||
| Line 77: | Line 83: | ||
*[[Air-kerma, product]] | *[[Air-kerma, product]] | ||
| + | |||
| + | *[[ALARA]] | ||
*ALI (see [[Annual limit on intake]]) | *ALI (see [[Annual limit on intake]]) | ||
| Line 83: | Line 91: | ||
*[[Alimentary tract transfer factor]] | *[[Alimentary tract transfer factor]] | ||
| + | |||
| + | *[[Allometry]] | ||
*[[Alpha decay]] | *[[Alpha decay]] | ||
| Line 129: | Line 139: | ||
*[[Background dose (rate)]] | *[[Background dose (rate)]] | ||
| + | |||
| + | *[[Backscatter detection system]] | ||
*[[Backscatter factor]] | *[[Backscatter factor]] | ||
| Line 211: | Line 223: | ||
*[[Class SR-2 gases]] | *[[Class SR-2 gases]] | ||
| + | |||
| + | *[[Clearance]] | ||
*[[Clearance level]] | *[[Clearance level]] | ||
| Line 237: | Line 251: | ||
*[[Colony]] | *[[Colony]] | ||
| + | |||
| + | *[[Commissioning]] | ||
*[[Committed effective dose]] | *[[Committed effective dose]] | ||
| Line 243: | Line 259: | ||
*[[Compartment]] | *[[Compartment]] | ||
| + | |||
| + | *[[Compartment (environmental)]] | ||
*[[Complex tissues]] | *[[Complex tissues]] | ||
*[[Computed tomography dose index]] | *[[Computed tomography dose index]] | ||
| + | |||
| + | *[[Concentration ratio]] | ||
*[[Cone beam computed tomography]] | *[[Cone beam computed tomography]] | ||
| Line 255: | Line 275: | ||
*[[Constancy test]] | *[[Constancy test]] | ||
| + | |||
| + | *[[Containment]] | ||
*[[Contamination]] | *[[Contamination]] | ||
*[[Coronary heart disease]] | *[[Coronary heart disease]] | ||
| + | |||
| + | *[[Cosmic radiation]] | ||
*[[Cost-benefit analysis]] | *[[Cost-benefit analysis]] | ||
*[[Coster-Kronig transition]] | *[[Coster-Kronig transition]] | ||
| + | |||
| + | *CR (see [[Concentration ratio]]) | ||
*[[Cross section]] | *[[Cross section]] | ||
| Line 279: | Line 305: | ||
*DBT (see [[Digital breast tomosynthesis]]) | *DBT (see [[Digital breast tomosynthesis]]) | ||
| + | |||
| + | *DCRL (see [[Derived consideration reference level]]) | ||
*DD (see [[Doubling dose]]) | *DD (see [[Doubling dose]]) | ||
| Line 301: | Line 329: | ||
*[[Derived air concentration]] | *[[Derived air concentration]] | ||
| + | |||
| + | *[[Derived consideration reference level]] | ||
*[[Derived investigation level]] | *[[Derived investigation level]] | ||
| + | |||
| + | *[[Derived limit]] | ||
| + | |||
| + | *[[Derived reference level]] | ||
| + | |||
| + | *[[Designated area]] | ||
*Detector dose indicator (see [[Exposure index]]) | *Detector dose indicator (see [[Exposure index]]) | ||
| Line 443: | Line 479: | ||
*[[Emergency procedures]] | *[[Emergency procedures]] | ||
| + | |||
| + | *[[Employer]] | ||
*[[Endogeneous excretion]] | *[[Endogeneous excretion]] | ||
| Line 473: | Line 511: | ||
*[[Ethics]] | *[[Ethics]] | ||
| + | |||
| + | *[[Evacuation]] | ||
*[[Excess absolute risk]] | *[[Excess absolute risk]] | ||
| Line 481: | Line 521: | ||
*[[Excretion rate (instantaneous)]] | *[[Excretion rate (instantaneous)]] | ||
| + | |||
| + | *[[Exclusion]] | ||
*[[Exempt waste]] | *[[Exempt waste]] | ||
| Line 495: | Line 537: | ||
*[[Exponential survival curve]] | *[[Exponential survival curve]] | ||
| + | |||
| + | *[[Exposed individuals]] | ||
*[[Exposure, external or internal]] | *[[Exposure, external or internal]] | ||
| Line 531: | Line 575: | ||
*[[Fractionation sensitivity]] | *[[Fractionation sensitivity]] | ||
| + | |||
| + | *[[Frequent flyer]] | ||
*FSU (see [[Functional subunits]]) | *FSU (see [[Functional subunits]]) | ||
Revision as of 16:08, 28 March 2021
The ICRP Glossary collects ICRP’s definitive explanations of terms for current use. Some entries include historical descriptions to help readers better understand the term in a particular context.
It is a living document, updated regularly.
Many ICRP publications feature their own glossaries including, for example, highly specialized terms relevant to that specific publication or helpful for a reader to have close at hand, or when introducing new terms to be added to the ICRP Glossary.
Although the ICRP Glossary is not a dictionary, terms already well covered in the Oxford English Dictionary are not included here unless further explanation is needed to understand the way in which these terms are used in ICRP publications.
| 0-9 | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | ... |
0-9
- 4DCT (see Time-resolved computed tomography)
A
- Acute radiation sickness (see Acute radiation syndrome)
- ALI (see Annual limit on intake)
- AMAD (see Activity median aerodynamic diameter)
- Ambient dose equivalent, H*(10)
- ARS (see Acute radiation syndrome)
B
- BAT (see Best available techniques)
- Bcr/abl (see Breakpoint cluster region/abelson)
C
- CACA (see Cobblestone area forming cell assay)
- CAFC (see Cobblestone area forming cell assay)
- CBCT (see Cone beam computed tomography)
- Cobblestone area cell assay (see Cobblestone area forming cell assay)
- CR (see Concentration ratio)
D
- DAC (see Derived air concentration)
- DBT (see Digital breast tomosynthesis)
- DCRL (see Derived consideration reference level)
- DD (see Doubling dose)
- DDI, detector dose indicator (see Exposure index)
- DIL (see Derived investigation level)
- DDREF (see Dose and dose-rate effectiveness factor)
- Detector dose indicator (see Exposure index)
- Directional dose equivalent H’(d,Ω)
- DLP (see Dose-length product)
- Dose (of ionising radiation)
- DQE (see Detector quantum efficiency)
- DRL (see Diagnostic reference level)
E
- EAR (see Excess absolute risk)
- EI (see Exposure index)
- ELR (i.e. Excess Lifetime Risk, see Lifetime risk estimates)
- Endosteal tissue (see Endosteum)
- ERR (see Excess relative risk)
- Excess lifetime risk (see Lifetime risk estimates)
F
- Fluence, Φ
- FSU (see Functional subunits)
G
- GATA-2 (see GATA binding protein 2)
- Gray (Gy)
H
- HATM (see Human Alimentary Tract Model]
I
- IMRT (see Intensity-modulated radiotherapy)
- Incidence rate (see Incidence)
J
K
- Kerma, K
L
- LET (see *Linear energy transfer)
- LLE (see Lifetime risk estimates)
- Loss of Life Expectancy (see Lifetime risk estimates)
- LSS (see Life Span Study)
M
- MDCT (see Multi-detector computed tomography)
- MMD (see *Mass median diameter)
N
- NHEJ (see Non-homologous end joining)
O
- OAR (see Organ at risk)
- OEA (see Oxygen enhancement ratio)
P
- Particle fluence (see Fluence)
- Personal dose equivalent, Hp(d)
- PLDR (see Potentially lethal damage repair)
Q
- Quality factor, Q(L)
R
- Radiation detriment (see Detriment)
- RAP (see Reference Animal and Plant)
- RBE (see Relative biological effectiveness)
- Reference female (see Reference Individual)
- Reference male (see Reference Individual)
- REID (see Lifetime risk estimates)
- Response function (see Dose-response function)
- Risk of exposure-induced death (see (see Lifetime risk estimates)
- ROS (see Reactive oxygen species)
- RR (see Relative risk)
S
- S coefficient (radiation weighted) SW[(rT←rs)]
- SAF (see Specific absorbed fraction)
- SEE (see Specific effective energy]
- Sievert (Sv)
- SLDR (see Sublethal damage repair)
- Slice (in CT & CBCT)
- SOBP (see Spread-out Bragg peak)
- Source (see Radiation source)
T
- Transport of risk (see Transfer of risk)
U
V
W
- wT (see Tissue weighting factor)
- wR (see Radiation weighting factor)
X
Y
Z
...
- α/β ratio (see α/β value)
